|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
1995-4-4
|
|
pubmed:abstractText |
The product of the HER2 protooncogene, p185HER2, represents an attractive target for cancer immunotherapies. We have prepared anti-p185HER2 immunoliposomes in which Fab' fragments of a humanized anti-p185HER2 monoclonal antibody with antiproliferative properties (rhuMAb-HER2) were conjugated to either conventional or sterically stabilized liposomes. These immunoliposomes bind specifically to p185HER2-overexpressing breast cancer cells (SK-BR-3 and BT-474). High-affinity binding of anti-p185HER2 immunoliposomes is comparable to that of free rhuMAbHER2-Fab' or the intact antibody. Empty immunoliposomes inhibit the culture growth of p185HER2-overexpressing breast cancer cells, and this antiproliferative effect is superior to that of free rhuMAbHER2-Fab', indicating that liposomal anchoring of these anti-p185HER2 Fab' fragments enhances their biological activity. Efficient internalization of anti-p185HER2 immunoliposomes, demonstrated by light and electron microscopy, occurs by receptor-mediated endocytosis via the coated pit pathway and also possibly by membrane fusion. Doxorubicin-loaded anti-p185HER2 immunoliposomes are markedly and specifically cytotoxic against p185HER2-overexpressing tumor cells in vitro. Anti-p185HER2 immunoliposomes administered in vivo in Scid mice bearing human breast tumor (BT-474) xenografts can deliver doxorubicin to tumors. These results indicate that anti-p185HER2 immunoliposomes are a promising therapeutic vehicle for the treatment of p185HER2-overexpressing human cancers.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/7877976-1350088,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7877976-1368228,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7877976-1426260,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7877976-1458465,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7877976-1543703,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7877976-1688187,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7877976-1763060,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7877976-1973830,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7877976-2065067,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7877976-2470152,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7877976-2566907,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7877976-2788031,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7877976-279908,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7877976-6251878,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7877976-6404557,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7877976-7053372,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7877976-7908410,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7877976-7908437,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7877976-7911565,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7877976-8101229,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7877976-8102322,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7877976-8453612
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0027-8424
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
28
|
|
pubmed:volume |
92
|
|
pubmed:geneSymbol |
HER2,
c-erbB2,
neu
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
N
|
|
pubmed:pagination |
1327-31
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:7877976-Animals,
pubmed-meshheading:7877976-Antibodies, Monoclonal,
pubmed-meshheading:7877976-Doxorubicin,
pubmed-meshheading:7877976-Endocytosis,
pubmed-meshheading:7877976-Female,
pubmed-meshheading:7877976-Growth Inhibitors,
pubmed-meshheading:7877976-Humans,
pubmed-meshheading:7877976-Liposomes,
pubmed-meshheading:7877976-Mice,
pubmed-meshheading:7877976-Mice, SCID,
pubmed-meshheading:7877976-Receptor, erbB-2,
pubmed-meshheading:7877976-Tumor Cells, Cultured
|
|
pubmed:year |
1995
|
|
pubmed:articleTitle |
Development of anti-p185HER2 immunoliposomes for cancer therapy.
|
|
pubmed:affiliation |
Department of Medicine, University of California, San Francisco 94143.
|
|
pubmed:publicationType |
Journal Article,
In Vitro,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
